Current Report Filing (8-k)

0000855654false00008556542021-10-292021-10-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

​

Washington, D.C. 20549

​

FORM 8-K

​

CURRENT REPORT

​

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

​

Date of Report (Date of earliest event reported): October 29, 2021

​

ImmunoGen, Inc.

(Exact name of registrant as specified in its charter)

​

​	​	​
​	​	​
Massachusetts	0-17999	04-2726691
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

​

830 Winter Street, Waltham, MA 02451

(Address of principal executive offices) (Zip Code)

​

Registrant's telephone number, including area code: [phone]

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

​

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​	​	​	​	​	​	​
​	Title of Each Class		Trading Symbol		Name of Each Exchange on Which Registered	​
​	Common Stock, $.01 par value	​	IMGN	​	Nasdaq Global Select Market	​

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter.

​

Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

ITEM 2.02 – RESULTS OF OPERATION AND FINANCIAL CONDITION

​

On October 29, 2021, ImmunoGen, Inc. (Nasdaq: IMGN) issued a press release to announce the company’s financial results for the quarter and nine months ended September 30, 2021. The press release announcing financial results for the quarter and nine months ended September 30, 2021 is included as Exhibit 99.1 and incorporated herein by reference.

​

​

​

​

ITEM 9.01 Financial Statements and Exhibits.

​

(d): Exhibits

​

Exhibit No.		Exhibit
​	​	​
99.1	​	Press Release of ImmunoGen, Inc. dated October 29, 2021
​	​	​
104	​	Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document).

​

​

​

​

​

​

​

​

​

​

SIGNATURES

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​

​
​	ImmunoGen, Inc.
​	(Registrant)
​	​
Date: October 29, 2021	/s/ Renee Lentini
​	Renee Lentini
​	Vice President, Chief Accounting Officer
​	​

​

​

​

​